Cadent Capital Advisors’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$551K Buy
2,081
+10
+0.5% +$2.64K 0.12% 117
2026
Q2
$526K Buy
2,071
+11
+0.5% +$2.56K 0.11% 120
2026
Q1
$504K Sell
2,060
-203
-9% -$47.3K 0.13% 103
2025
Q4
$468K Sell
2,263
-12
-0.5% -$2.37K 0.12% 110
2025
Q3
$422K Buy
+2,275
New +$390K 0.11% 125
2024
Q2
– Sell
-1,783
Closed -$282K – 150
2024
Q1
$282K Buy
1,783
+2
+0.1% +$318 0.11% 103
2023
Q4
$279K Sell
1,781
-17
-0.9% -$2.61K 0.14% 90
2023
Q3
$280K Buy
1,798
+22
+1% +$3.63K 0.12% 86
2023
Q2
$294K Buy
1,776
+327
+23% +$52.8K 0.18% 90
2023
Q1
$225K Buy
1,449
+3
+0.2% +$484 0.1% 116
2022
Q4
$255K Buy
1,446
+122
+9% +$21.1K 0.13% 98
2022
Q3
$216K Buy
1,324
+9
+0.7% +$1.52K 0.12% 98
2022
Q2
$233K Sell
1,315
-165
-11% -$29.4K 0.13% 97
2022
Q1
$262K Buy
1,480
+280
+23% +$47.6K 0.12% 109
2021
Q4
$205K Sell
1,200
-79
-6% -$12.9K 0.09% 123
2021
Q3
$207K Hold
1,279
– – 0.09% 123
2021
Q2
$211K Buy
1,279
+1
+0.1% +$166 0.09% 131
2021
Q1
$210K Buy
+1,278
New +$207K 0.09% 125

Other funds holding JNJ

Cadent Capital Advisors's JNJ Position: Q3 2026 in Review

Cadent Capital Advisors increased its Johnson & Johnson (JNJ) stake by 0.48% in Q3 2026, buying an estimated $2.64K and bringing the position to 2,081 shares worth $551K. The position accounts for 0.12% of the portfolio, ranked #117.

Cadent Capital Advisors first reported a position in JNJ in Q1 2021 and has held it in 18 quarters since. 453 funds tracked by Wall St. Rank hold JNJ as of Q3 2026.

  • Cadent Capital Advisors held 2,081 shares of Johnson & Johnson worth $551K as of Q3 2026.
  • Cadent Capital Advisors bought 10 Johnson & Johnson shares in Q3 2026, an estimated $2.64K.
  • Johnson & Johnson made up 0.12% of Cadent Capital Advisors's portfolio in Q3 2026, its #117 holding.
  • Cadent Capital Advisors first reported a position in Johnson & Johnson in Q1 2021 and has held it in 18 quarters since.
  • 453 funds tracked by Wall St. Rank held Johnson & Johnson as of Q3 2026.

Based on Cadent Capital Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.